Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T39273 |
Lumasiran
ALN-G01 |
||
Lumasiran (ALN-G01), a siRNA product, inhibits hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes this enzyme and thereby prevents the synthesis of oxalate, the toxic metabolite directly linked to the clinical manifestations of Primary hyperoxaluria type 1 (PH1). | |||
T39274 |
Lumasiran sodium
|
||
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production, thereby reducing urinary oxalate excretion. This compound shows promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1). |